Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biogen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Biogen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Biogen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Biogen Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Biogen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biogen Inc, Medical Equipment, Deal Details 11
Partnerships 11
Biogen Expands Licensing Agreement with Absorption Systems 11
Siemens Healthcare Enters into Co-Development Agreement with Biogen 12
Enigma Biomedical Enters into Research Agreement with Biogen and Merck 13
AC Immune Enters into Partnership with Biogen 14
Oklahoma Medical Research Foundation Enters into Research Agreement with Biogen 15
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 16
Regulus Therapeutics Amends Agreement With Biogen Idec 17
Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 18
Orasi Medical Enters Into An Agreement With Biogen Idec 19
Debt Offering 20
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 20
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 22
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 24
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 26
Acquisition 28
Bristol-Myers Rumored To Acquire Biogen Idec 28
Biogen Inc – Key Competitors 29
Biogen Inc – Key Employees 30
Biogen Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 36
Recent Developments 37
Financial Announcements 37
Oct 24, 2017: Biogen Reports Quarterly Revenues of $3.1 Billion 37
Jul 25, 2017: Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance 39
Apr 25, 2017: Biogen Reports First Quarter 2017 Revenues of $2.8 Billion 42
Jan 26, 2017: Biogen Reports 2016 Revenues of $11.4 Billion 44
Oct 26, 2016: Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion 46
Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion 48
Corporate Communications 51
Dec 04, 2017: Biogen Appoints Mark Hernon as SVP, Chief Information Officer 51
Nov 21, 2017: Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer 52
Nov 02, 2017: Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation 53
Sep 12, 2017: Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical 54
Jul 31, 2017: Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences 55
Jul 24, 2017: Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations 56
Jul 10, 2017: Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs 57
Jun 28, 2017: Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs 58
Jun 20, 2017: Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer 59
Jun 14, 2017: Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations 60
Jun 13, 2017: Biogen Announces Management Change 61
Mar 16, 2017: Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development 62
Dec 19, 2016: Biogen Names Michel Vounatsos Chief Executive Officer 63
Nov 15, 2016: Biogen announces management changes 64
Jun 21, 2016: Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology 65
Legal and Regulatory 66
Sep 05, 2017: Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit 66
May 01, 2017: Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement 67
Feb 09, 2017: Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen 68
Jan 12, 2017: Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock 69
Other Significant Developments 70
Jun 14, 2017: Accenture Labs and 1QBit Work with Biogen to Apply Quantum Computing to Accelerate Drug Discovery 70
Dec 22, 2016: Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement 71
Nov 30, 2016: Sangamo’s Genome Editing Program for Hemoglobinopathies to Transfer to Biogen’s Spin-Off Bioverativ 72
Jul 22, 2016: Medidata Cloud Technology Selected to Support Biogen Clinical Trials 73
Jun 28, 2016: Biogen Selects Cognizant’s SmartTrials Platform 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75
Biogen Inc, Medical Equipment, Key Facts, 2016 2
Biogen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Biogen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Biogen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Biogen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Biogen Inc, Deals By Market, 2011 to YTD 2017 9
Biogen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biogen Expands Licensing Agreement with Absorption Systems 11
Siemens Healthcare Enters into Co-Development Agreement with Biogen 12
Enigma Biomedical Enters into Research Agreement with Biogen and Merck 13
AC Immune Enters into Partnership with Biogen 14
Oklahoma Medical Research Foundation Enters into Research Agreement with Biogen 15
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 16
Regulus Therapeutics Amends Agreement With Biogen Idec 17
Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 18
Orasi Medical Enters Into An Agreement With Biogen Idec 19
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 20
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 22
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 24
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 26
Bristol-Myers Rumored To Acquire Biogen Idec 28
Biogen Inc, Key Competitors 29
Biogen Inc, Key Employees 30
Biogen Inc, Other Locations 32
Biogen Inc, Subsidiaries 32
Biogen Inc, Joint Venture 36